Clinical considerations in Parkinson's disease cell therapy

被引:6
作者
Xue, Jun [1 ,2 ]
Wu, Yifan [1 ,2 ]
Bao, Yuting [1 ,2 ]
Zhao, Minglai [1 ,2 ]
Li, Fangzhou [1 ,2 ]
Sun, Jing [3 ]
Sun, Yimin [4 ]
Wang, Jian [4 ]
Chen, Liang [1 ,2 ]
Mao, Ying [1 ,2 ]
Schweitzer, Jeffrey S. [5 ]
Song, Bin [1 ,2 ]
机构
[1] Fudan Univ, Huashan Hosp, Dept Neurosurg, Shanghai 200040, Peoples R China
[2] Fudan Univ, Shanghai Clin Med Ctr Neurosurg, Neurosurg Inst,Shanghai Key Lab Brain Funct & Res, Natl Ctr Neurol Disorders, Shanghai 200040, Peoples R China
[3] Fudan Univ, MOE Frontiers Ctr Brain Sci, Inst Translat Brain Res, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China
[4] Fudan Univ, Huashan Hosp, Shanghai Med Coll, Inst Neurol,Natl Clin Res Ctr Aging & Med, Shanghai 200032, Peoples R China
[5] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA
基金
上海市自然科学基金; 中国国家自然科学基金;
关键词
Parkinson?s disease; Cell therapy; Dopamine cells; Transplantation; Clinical trial; FETAL DOPAMINE NEURONS; IMPROVES XENOGRAFT SURVIVAL; GRAFT-INDUCED DYSKINESIAS; RIGHT CAUDATE-NUCLEUS; LONG-TERM SURVIVAL; MESENCEPHALIC TISSUE; PRIMATE MODEL; NIGRAL TRANSPLANTATION; GENE-THERAPY; NEURAL PROGENITORS;
D O I
10.1016/j.arr.2022.101792
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Cell replacement therapy is an area of increasing interest for treating Parkinson's disease (PD). However, to become a clinically practical option for PD patients, it must first overcome significant barriers, including establishment of safe and standardized surgical procedures, determination of appropriate perioperative medication regimens, demonstration of long-term graft survival and incorporation, and standardized, clinically meaningful follow-up measures. In this review, we will describe the current status of cell therapy for PD with special attention to these critical requirements, to define guideposts on the road to bring the benefit of this therapy to the Parkinson's clinic.
引用
收藏
页数:20
相关论文
共 50 条
  • [21] Cell therapy and other neuroregenerative strategies in Parkinson's disease (II)
    Mínguez-Castellanos, A
    Escamilla-Sevilla, F
    REVISTA DE NEUROLOGIA, 2005, 41 (11) : 684 - 693
  • [22] Cell therapy and other neuroregenerative strategies in Parkinson's disease (I)
    Mínguez-Castellanos, A
    Escamilla-Sevilla, F
    REVISTA DE NEUROLOGIA, 2005, 41 (10) : 604 - 614
  • [23] Surgical therapy for Parkinson's disease
    Olanow, CW
    EUROPEAN JOURNAL OF NEUROLOGY, 2002, 9 : 31 - 39
  • [24] The search for a curative cell therapy in Parkinson's disease
    Goya, R. Laguna
    Tyers, P.
    Barker, R. A.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2008, 265 (1-2) : 32 - 42
  • [25] Stem cells for cell therapy in Parkinson's disease
    Lindvall, O
    PHARMACOLOGICAL RESEARCH, 2003, 47 (04) : 279 - 287
  • [26] Cell-based therapies for Parkinson's disease
    Dyson, Sean C.
    Barker, Roger A.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2011, 11 (06) : 831 - 844
  • [27] Cell Therapy for Parkinson's Disease
    Morizane, Asuka
    Takahashi, Jun
    NEUROLOGIA MEDICO-CHIRURGICA, 2016, 56 (03) : 102 - 109
  • [28] Cell Therapy for Parkinson's Disease
    Shastry, Surabhi
    Hu, Junkai
    Ying, Mingyao
    Mao, Xiaobo
    PHARMACEUTICS, 2023, 15 (12)
  • [29] Apomorphine for Parkinson's disease: pharmacologic and clinical considerations
    Wagner, Maxwell J.
    Daniel, Charles P.
    Plaisance, Connor J.
    Borne, Grant E.
    Ahmadzadeh, Shahab
    Shekoohi, Sahar
    Kaye, Alan D.
    EXPERT OPINION ON EMERGING DRUGS, 2023, 28 (04) : 275 - 281
  • [30] Treatment of Parkinson's disease using cell transplantation
    Lindvall, Olle
    PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, 2015, 370 (1680)